300765:SZSECSPC Innovation Pharmaceutical Co., Ltd. Class A Analysis

CSPC Innovation Pharmaceutical is posting **robust revenue growth of 40.8%** while still operating at a **‑17% operating margin** and a **‑13% net profit margin**, resulting in a **trailing EPS of –0.22** and a **forward EPS of 0.81**. The stock trades at a **forward P/E of 41.7**, a **price‑to‑book of 18.3** and a **price‑to‑sales of 20.2**, far above sector averages, and the DCF model values the company at only **¥5.15**, implying a **massive valuation gap** despite analysts’ median target of ¥45. Technically, the MACD is bullish and the RSI sits at 65.4 (near overbought), yet the price remains **below the 200‑day SMA (34.73)**, signalling a **bearish longer‑term trend** with support at ¥23.05 and resistance at ¥38.67. Volatility is high at **~75%** over the past 30 days, though beta is low (0.24), and volume is increasing, indicating strong trading interest.
The company’s balance sheet is solid with **¥978 m of cash** versus **¥12 m of debt**, and free cash flow is positive at **¥175 m**, but operating cash flow is negative, and ROE is **‑16.9%**, raising doubts about the **sustainability of the modest 0.08% dividend**. Given the over‑inflated multiples, negative earnings, and regulatory exposure in the Chinese pharma/food space, the stock appears **overvalued in the near term**, while the growth narrative may justify a more neutral stance over a longer horizon if profitability improves.